A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00138762|
Recruitment Status : Completed
First Posted : August 30, 2005
Last Update Posted : February 17, 2012
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
A study to look at lipid levels in subjects taking the study drug, Atorvastatin alone or placebo.
|Condition or disease||Intervention/treatment||Phase|
|Hyperlipidemia||Drug: torcetrapib/atorvastatin Drug: atorvastatin Drug: placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||3800 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|
|Study Start Date :||July 2004|
|Actual Primary Completion Date :||August 2006|
|Actual Study Completion Date :||August 2006|
- LDL and HDL levels
- other lipid parameters
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00138762
|Study Director:||Pfizer CT.gov Call Center||Pfizer|